Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
PhRMA Wants No Off-Year Price Cuts, Urges Japan Not to Backslide: Chair
Japan must stay on its pro-innovation path for pharmaceutical policies with the FY2024 reform as a starting point and not backslide by expanding “off-year” drug price revisions, said Daniel O’Day, chair of the Pharmaceutical Research and Manufacturers of America (PhRMA),…
To read the full story
Related Article
ORGANIZATION
- 3 Pharma Groups Press Government to Rethink CEA Expansion
October 8, 2026
- JPMA Chief Urges Manufacturing, Talent Push to Build Drug Discovery Ecosystem
October 8, 2026
- PhRMA Taps Jonathan Kushner as New Japan Representative
October 6, 2026
- 60% of EFPIA Firms Could Cut Japan Trial Investments without Policy Reform
October 2, 2026
- JPMA to Complete Shift to Legal Entity on October 1
September 30, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…